Grant: Master's Award: Canada Graduate Scholarships
University of British Columbia
$17,500.00
Making an unlimited source of regulatory T cells for cell therapy
FY 2022-23
Summary
In patients undergoing transplant rejection or autoimmune attack, the body’s immune balance is disrupted. There is an imbalance between inflammatory conventional T (Tconv) cells and immune-suppressive regulatory T (Treg) cells. To restore immune balance, Tregs can be administered into patients to promote localized immune suppression at a specific part of the body. Unfortunately, Tregs are very rare blood cells, and they cannot be isolated from all people, making it difficult to make them available to everyone who could benefit. This issue can be solved by using pluripotent stem cells (PSCs) instead as a starting material to make Tregs. PSCs are cells that are renewable and can mature into any cell type within the body – given the right stimuli. My project aims to create a novel method to generate a sustainable and ready source of therapeutic Tregs by making them from PSCs. First, I will study how Tregs develop typically in the human thymus, an organ that produces Tregs and Tconvs. Using single cell sequencing and high resolution imaging, I will determine how Treg progenitors interact with other cell types within the thymus, allowing identification of interactions that are crucial for progenitors to commit into Treg lineage. By modifying existing protocols for making Tconvs from PSCs, I will apply findings from the thymus to see if I can develop Tregs from PSCs through the use of molecules or genetic engineering. The resulting cells will be assessed for Treg-specific characteristics and for their ability to suppress inflammatory immune cells. Overall, this study will expand our understanding of Treg development and create new ways to make Treg cell therapy more feasible to treat patients with autoimmunity or transplant rejection.
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
British Columbia, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
486086
Name
Salim Kevin
Region
British Columbia
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Making an unlimited source of regulatory T cells for cell therapy
Programtype2
Studentship Programs
Orgnameinp2
University of British Columbia
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Diabetes; Flow Cytometry; Immunotherapy; Multiplexed Imaging; Pluripotent Stem Cells; Regulatory T Cells; Single Cell Sequencing; Stem Cell-Derived Products; Thymus; Transplant
Abstract
In patients undergoing transplant rejection or autoimmune attack, the body’s immune balance is disrupted. There is an imbalance between inflammatory conventional T (Tconv) cells and immune-suppressive regulatory T (Treg) cells. To restore immune balance, Tregs can be administered into patients to promote localized immune suppression at a specific part of the body. Unfortunately, Tregs are very rare blood cells, and they cannot be isolated from all people, making it difficult to make them available to everyone who could benefit. This issue can be solved by using pluripotent stem cells (PSCs) instead as a starting material to make Tregs. PSCs are cells that are renewable and can mature into any cell type within the body – given the right stimuli. My project aims to create a novel method to generate a sustainable and ready source of therapeutic Tregs by making them from PSCs. First, I will study how Tregs develop typically in the human thymus, an organ that produces Tregs and Tconvs. Using single cell sequencing and high resolution imaging, I will determine how Treg progenitors interact with other cell types within the thymus, allowing identification of interactions that are crucial for progenitors to commit into Treg lineage. By modifying existing protocols for making Tconvs from PSCs, I will apply findings from the thymus to see if I can develop Tregs from PSCs through the use of molecules or genetic engineering. The resulting cells will be assessed for Treg-specific characteristics and for their ability to suppress inflammatory immune cells. Overall, this study will expand our understanding of Treg development and create new ways to make Treg cell therapy more feasible to treat patients with autoimmunity or transplant rejection.
Competitiondate
202212
Approvedterm2
1 yr 0 mth
Pinamesdelim
Salim, Kevin
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~